Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

PF-06881894

Alternative Names: pf-06881894, pf 06881894, pf06881894
Latest Update: 2025-02-26
Latest Update Note: Clinical Trial Update

Product Description

PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta) the recombinant human granulocyte colony-stimulating factor analog filgrastim. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32524499/)

Mechanisms of Action: G-CSF Stimulant

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Teratoma|Choriocarcinoma|Germinoma|Mixed Tumor, Malignant|Embryonal Carcinoma|Endodermal Sinus Tumor

Phase 1: Febrile Neutropenia|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ACNS2021

P2

Recruiting

Mixed Tumor, Malignant|Choriocarcinoma|Embryonal Carcinoma|Germinoma|Endodermal Sinus Tumor|Teratoma

2029-12-21

C1221007

P1

Completed

Febrile Neutropenia

2022-08-10

C1221005

P1

Completed

Healthy Volunteers

2018-07-25

28%

Recent News Events

Date

Type

Title

12/01/2021

PubMed

 Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.

07/01/2020

PubMed

 PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta()): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions